Model: immobilized AURKA. Treatment: increasing concentrations. Result: Kd 2.28 ± 0.03 nM. Bovine oocytes were treated with the study compound in maturation medium for 23 h. Levels of phosphorylated TACC3 (pTACC3) decreased to 77% of the control levels. HeLa cells received inhibitor treatment at 0.5 µM during the final hour of washout, with each condition compared with its corresponding untreated control. Treatment reduced S69 phosphorylation to a greater extent than S55 phosphorylation and even more so than S44 phosphorylation. Model: purified kinase domain of AURKA. Treatment: 0.15 nM, 0.31 nM, 0.62 nM, 1.25 nM, 2.5 nM, 5 nM, 10 nM, 20 nM, 40 nM, 80 nM, and 160 nM. Result: IC50 = 6 nM. [1,2,3]
Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.
equilibrium dissociation constant (Kd) in immobilized AURKA
Cell-based study · immobilized AURKA [1]
Model: immobilized AURKA. Treatment: increasing concentrations. Result: Kd 2.28 ± 0.03 nM.
Literature-Reported Treatment Conditions
- Treatment concentration
- increasing concentrations
- Exposure duration
- A dissociation of 180 s
- Method
- injected at different concentrations onto the sensor chip
- Vehicle
- 10 mM Hepes pH 7.4, 150 mM NaCl, 1% DMSO, 0.005% Tween20
Methods and source locations
Compound reported in the paper: MLN8054
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
2. Results > 2.2. PHA-680626 and RPM1722 Behave as CD Inhibitors In Vitro (S16, S17); 4. Materials and Methods > 4.5. Surface Plasmon Resonance (S93, S95, S100, S102, S111); Figure 2 legend (S163); Table 2 (T2.h1, T2.r2)
equilibrium dissociation constant (Kd): equilibrium dissociation constant (Kd); comparator: Flow cell Ch2 was left empty and used as a control — 4. Materials and Methods > 4.5. Surface Plasmon Resonance (S111); Table 2 (T2.h1, T2.r2)
Reduced Phosphorylated TACC3 Levels in Bovine Oocytes
Cell-based study · bovine oocytes [2]
Bovine oocytes were treated with the study compound in maturation medium for 23 h. Levels of phosphorylated TACC3 (pTACC3) decreased to 77% of the control levels.
Literature-Reported Treatment Conditions
- Exposure duration
- 23 h
- Method
- in maturation medium
- Vehicle
- dimethyl sulfoxide (DMSO)
- Reported limits
- Not stated in the sentences used: dose.
Methods and source locations
Compound reported in the paper: MLN8054
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Materials and Methods > Aurora A kinase inhibition (S50, S51); Results > Indirect inhibition of TACC3 using MLN8054 disrupts meiotic spindle formation in a dose-dependent manner (S101)
levels of phosphorylated TACC3 (pTACC3): levels of phosphorylated TACC3 (pTACC3); comparator: normal maturation medium, or maturation medium containing DMSO (0.02%) — Results > Indirect inhibition of TACC3 using MLN8054 disrupts meiotic spindle formation in a dose-dependent manner (S101)
Inhibitor treatment and phosphorylation in HeLa cells
Cell-based study · HeLa cells [3]
HeLa cells received inhibitor treatment at 0.5 µM during the final hour of washout, with each condition compared with its corresponding untreated control. Treatment reduced S69 phosphorylation to a greater extent than S55 phosphorylation and even more so than S44 phosphorylation.
Literature-Reported Treatment Conditions
- Treatment concentration
- 0.5 µM
- Exposure duration
- treated in the final hour of washout (9–10 h after washout)
- Co-treatment
- Other interventions in this design: thymidine. Compound effect isolated by the comparison: each condition is compared with the corresponding untreated control.
- Reported limits
- Not stated in the sentences used: route, vehicle.
Methods and source locations
Compound reported in the paper: MLN8054
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Results (S17); Materials and methods > Cell treatments and transfections (S110, S111); Materials and methods > Immunofluorescence (S117); Figure 3. legend (S236, S239); Figure 5. legend (S251, S257)
S69 phosphorylation: S69 phosphorylation; comparator: corresponding untreated control — Results (S17)
kinase activity of AURKA in purified kinase domain of AURKA
Biochemical assay · purified kinase domain of AURKA [1]
Model: purified kinase domain of AURKA. Treatment: 0.15 nM, 0.31 nM, 0.62 nM, 1.25 nM, 2.5 nM, 5 nM, 10 nM, 20 nM, 40 nM, 80 nM, and 160 nM. Result: IC50 = 6 nM.
Literature-Reported Treatment Conditions
- Treatment concentration
- 0.15 nM, 0.31 nM, 0.62 nM, 1.25 nM, 2.5 nM, 5 nM, 10 nM, 20 nM, 40 nM, 80 nM, and 160 nM
- Exposure duration
- incubation at room temperature for 30 min
- Vehicle
- inhibitor solubilized in 100% DMSO
- Reported limits
- Not stated in the sentences used: route, control.
Methods and source locations
Compound reported in the paper: MLN8054
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
2. Results > 2.2. PHA-680626 and RPM1722 Behave as CD Inhibitors In Vitro (S12); 4. Materials and Methods > 4.4. Kinase Activity Assays (S85, S86, S87, S88, S89, S90); Table 1 (T1.h1, T1.r2)
kinase activity of AURKA: kinase activity of AURKA — 4. Materials and Methods > 4.4. Kinase Activity Assays (S90); Table 1 (T1.h1, T1.r2)